SCHEMBL202963

SCHEMBL202963

Nc1ccccc1OBOc1ccccc1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
TDP1 Q9NUW8 2/20 0.54
ADRA2B P18089 1/20 0.54
PTGS1 P23219 1/20 0.54
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
ALOX15 P16050 2/20 0.45
CYP3A4 P08684 2/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
GAA P10253 3/20 0.42
RCE1 Q9Y256 1/20 0.42
APP P05067 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1234308 0.97 ALDH1A1 (0.52) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL365525 0.80 ALDH1A1 (0.50) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL81185 0.75 KDM4E (0.65) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL29508342 0.75 KDM4E (0.65) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL863708 0.75 ALDH1A1 (0.62) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL30979203 0.75 KDM4E (0.65) ALDH1A1TDP1ADRA2BPTGS1MAPT
Biphenyl SCHEMBL2308329 0.73 ALDH1A1 (0.44) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL6289306 0.72 KDM4E (0.62) ALDH1A1TDP1ADRA2BPTGS1MAPT
SCHEMBL1361220 0.72 KDM4E (0.62) ALDH1A1TDP1ADRA2BPTGS1MAPT
Hydrochloric Acid SCHEMBL11737056 0.72 KDM4E (0.62) ALDH1A1TDP1ADRA2BPTGS1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12379383-B2 Proteoform specific process validation Novilytic, LLC (US) 2025-08-05 US claimed
EP-4204158-A1 PROTEOFORM SPECIFIC PROCESS VALIDATION Novilytic, LLC (US) 2023-07-05 EP claimed
US-20220137063-A1 Proteoform Specific Process Validation TENAX BIOANALYTICS, LLC 2022-05-05 US claimed
WO-2022060947-A1 PROTEOFORM SPECIFIC PROCESS VALIDATION Novilytic, LLC (US) 2022-03-24 WO claimed
US-10995104-B2 Catalysts for reversing formaldehyde adducts and crosslinks ROCHE MOLECULAR SYSTEM, INC. (US) 2021-05-04 US claimed
EP-3634470-A1 GLUCOSE SENSITIVE COMPOSITIONS FOR DRUG DELIVERY North Carolina State University (US) 2020-04-15 EP claimed
EP-3631408-A1 CATALYSTS FOR REVERSING FORMALDEHYDE ADDUCTS AND CROSSLINKS Roche Diagnostics GmbH (DE) 2020-04-08 EP claimed
US-20180370992-A1 Catalysts for reversing formaldehyde adducts and crosslinks ROCHE MOLECULAR SYSTEMS, INC. 2018-12-27 US claimed
WO-2018219997-A1 CATALYSTS FOR REVERSING FORMALDEHYDE ADDUCTS AND CROSSLINKS ROCHE DIAGNOSTICS GMBH (DE) 2018-12-06 WO claimed
WO-2018223114-A1 GLUCOSE SENSITIVE COMPOSITIONS FOR DRUG DELIVERY NORTH CAROLINA STATE UNIVERSITY (US) 2018-12-06 WO claimed
US-8557304-B2 Method of obtaining secondary plant constituents SARTORIUS STEDIM BIOTECH GMBH (DE) 2013-10-15 US claimed
US-20120077994-A1 METHOD OF OBTAINING SECONDARY PLANT CONSTITUENTS SARTORIUS STEDIM BIOTECH GMBH (DE) 2012-03-29 US claimed
EP-2268805-A1 LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE Halozyme, Inc. (US) 2011-01-05 EP claimed
WO-2009111066-A1 LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE HALOZYME, INC. (US) 2009-09-11 WO claimed
US-20070141678-A1 Processes for purifying oligosaccharides THE PROCTER & GAMBLE COMPANY 2007-06-21 US claimed
EP-4746986-A1 RADIAL FLOW SEPARATION DEVICE Astrea UK Services Limited (GB) 2026-05-27 EP disclosed
US-12600959-B2 PH20 polypeptide variants, formulations and uses thereof HALOZYME, INC. (US) 2026-04-14 US disclosed
EP-0487621-A4 IMMUNOASSAY OF GLYCOSYLATED PROTEINS EMPLOYING ANTIBODY DIRECTED TO REDUCTIVELY GLYCOSYLATED N-TERMINAL AMINO ACIDS 1992-06-24 EP disclosed
EP-0487621-A1 IMMUNOASSAY OF GLYCOSYLATED PROTEINS EMPLOYING ANTIBODY DIRECTED TO REDUCTIVELY GLYCOSYLATED N-TERMINAL AMINO ACIDS. UNIV NORTHWESTERN (US) 1992-06-03 EP disclosed
WO-1991002978-A1 IMMUNOASSAY OF GLYCOSYLATED PROTEINS EMPLOYING ANTIBODY DIRECTED TO REDUCTIVELY GLYCOSYLATED N-TERMINAL AMINO ACIDS NORTHWESTERN UNIVERSITY (US) 1991-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600959-B2 PH20 polypeptide variants, formulations and uses thereof PREP, HM13, MMP20 ALDH1A1 1859/4885TDP1 843/4885ADRA2B 4073/4885
US-20180370992-A1 Catalysts for reversing formaldehyde adducts and crosslinks FBL, PCNA, UNG ALDH1A1 724/4885TDP1 395/4885ADRA2B 4249/4885
US-10995104-B2 Catalysts for reversing formaldehyde adducts and crosslinks FBL, PCNA, UNG ALDH1A1 724/4885TDP1 395/4885ADRA2B 4249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.